81 related articles for article (PubMed ID: 27987232)
1. The paradoxical changes of membrane and soluble herpes virus entry mediator in hepatocellular carcinoma patients.
Zhao Q; Zhang GL; Zhu X; Su D; Huang ZL; Hu ZX; Peng L
J Gastroenterol Hepatol; 2017 Aug; 32(8):1520-1524. PubMed ID: 27987232
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of herpesvirus entry mediator expression in human hepatocellular carcinoma.
Hokuto D; Sho M; Yamato I; Yasuda S; Obara S; Nomi T; Nakajima Y
Eur J Cancer; 2015 Jan; 51(2):157-65. PubMed ID: 25468715
[TBL] [Abstract][Full Text] [Related]
3. The presence of high level soluble herpes virus entry mediator in sera of gastric cancer patients.
Heo SK; Ju SA; Kim GY; Park SM; Back SH; Park NH; Min YJ; An WG; Nguyen TT; Kim SM; Kim BS
Exp Mol Med; 2012 Feb; 44(2):149-58. PubMed ID: 22113134
[TBL] [Abstract][Full Text] [Related]
4. Distinct Changes of BTLA and HVEM Expressions in Circulating CD4
Liu J; Li J; He M; Zhang GL; Zhao Q
J Immunol Res; 2018; 2018():4561571. PubMed ID: 30116751
[TBL] [Abstract][Full Text] [Related]
5. Role of BTLA/HVEM network in development of gastric cancer.
Azarafza M; Tehrani M; Valadan R; Maleki I; Mohammad Mehdi Ghaffari-Hamedani S; Ghanadan A; Alizadeh-Navaei R; Ajami A
Hum Immunol; 2022; 83(8-9):637-644. PubMed ID: 35914980
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of herpes virus entry mediator expression in hepatitis B virus-related hepatocellular carcinoma.
Yi Y; Ni XC; Liu G; Yin YR; Huang JL; Gan W; Zhou PY; Guan RY; Zhou C; Sun BY; Qiu SJ
Oncol Lett; 2020 Oct; 20(4):19. PubMed ID: 32774492
[TBL] [Abstract][Full Text] [Related]
7. High levels of soluble herpes virus entry mediator in sera of patients with allergic and autoimmune diseases.
Jung HW; La SJ; Kim JY; Heo SK; Kim JY; Wang S; Kim KK; Lee KM; Cho HR; Lee HW; Kwon B; Kim BS; Kwon BS
Exp Mol Med; 2003 Dec; 35(6):501-8. PubMed ID: 14749527
[TBL] [Abstract][Full Text] [Related]
8. Herpes Virus Entry Mediator (HVEM): A Novel Potential Mediator of Trauma-Induced Immunosuppression.
Wakeley ME; Shubin NJ; Monaghan SF; Gray CC; Ayala A; Heffernan DS
J Surg Res; 2020 Jan; 245():610-618. PubMed ID: 31522034
[TBL] [Abstract][Full Text] [Related]
9. Serum anti-osteopontin autoantibody as a novel diagnostic and prognostic biomarker in patients with hepatocellular carcinoma.
Ying X; Zhao Y; Wang JL; Zhou X; Zhao J; He CC; Guo XJ; Jin GH; Wang LJ; Zhu Q; Han SX
Oncol Rep; 2014 Oct; 32(4):1550-6. PubMed ID: 25109745
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma immunopathogenesis: clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25).
Cabrera R; Ararat M; Cao M; Xu Y; Wasserfall C; Atkinson MA; Liu C; Nelson DR
Dig Dis Sci; 2010 Feb; 55(2):484-95. PubMed ID: 19714465
[TBL] [Abstract][Full Text] [Related]
11. Characterization of herpes virus entry mediator as a factor linked to obesity.
Bassols J; Moreno JM; Ortega F; Ricart W; Fernandez-Real JM
Obesity (Silver Spring); 2010 Feb; 18(2):239-46. PubMed ID: 19680232
[TBL] [Abstract][Full Text] [Related]
12. Influence of hepatitis C virus infection on circulating levels of sICAM-1 and VEGF in patients with hepatitis C and hepatocellular carcinoma (HCC) and their role in enhancing detection of HCC.
Helaly GF; Abou Shamaa LA
Egypt J Immunol; 2006; 13(1):27-38. PubMed ID: 17974148
[TBL] [Abstract][Full Text] [Related]
13. Low herpesvirus entry mediator (HVEM) expression on dermal fibroblasts contributes to a Th2-dominant microenvironment in advanced cutaneous T-cell lymphoma.
Miyagaki T; Sugaya M; Suga H; Morimura S; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
J Invest Dermatol; 2012 Apr; 132(4):1280-9. PubMed ID: 22297640
[TBL] [Abstract][Full Text] [Related]
14. Detection of soluble tumor necrosis factor-p55 levels in the serum and ascitic fluid of patients with hepatocellular carcinoma.
Gao L; Bai L; Nan QZ; Yang XS; Chen K; Wen HP; Lai ZS; Bo L; Zhang YL; Zhang ZS
Di Yi Jun Yi Da Xue Xue Bao; 2002 Jul; 22(7):641-3. PubMed ID: 12376300
[TBL] [Abstract][Full Text] [Related]
15. Herpes virus entry mediator in human corneal epithelial cells modulates the production of inflammatory cytokines in response to HSV type 1 challenge.
Guo H; Pang K; Wei Y; Yi C; Wu X
Ophthalmic Res; 2015; 54(3):128-34. PubMed ID: 26328884
[TBL] [Abstract][Full Text] [Related]
16. Peripheral blood microvesicles are potential biomarkers for hepatocellular carcinoma.
Wang W; Li H; Zhou Y; Jie S
Cancer Biomark; 2013; 13(5):351-7. PubMed ID: 24440975
[TBL] [Abstract][Full Text] [Related]
17. Can we consider soluble herpes virus entry mediator (sHVEM) as a tumor marker?
Javadzadeh SM; Tehrani M; Keykhosravi M; Mohammadian-Amiri R; Amjadi O; Hafezi N; Zaboli E; Montazeriun M; Ajami A
Caspian J Intern Med; 2022; 13(4):693-698. PubMed ID: 36420330
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
[TBL] [Abstract][Full Text] [Related]
19. Expression and Clinical Significance of Herpes Virus Entry Mediator (HVEM) in Breast Cancer.
Tsang JYS; Chan KW; Ni YB; Hlaing T; Hu J; Chan SK; Cheung SY; Tse GM
Ann Surg Oncol; 2017 Dec; 24(13):4042-4050. PubMed ID: 28612127
[TBL] [Abstract][Full Text] [Related]
20. Potential therapeutic value of dendritic cells loaded with NY‑ESO‑1 protein for the immunotherapy of advanced hepatocellular carcinoma.
Chen Y; Huang A; Gao M; Yan Y; Zhang W
Int J Mol Med; 2013 Dec; 32(6):1366-72. PubMed ID: 24085111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
